Condition
Pancreatic Carcinoma Metastatic
Total Trials
5
Recruiting
0
Active
1
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results75% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 1 (2)
P 2 (2)
Trial Status
Completed3
Active Not Recruiting1
Terminated1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05642962Phase 1Active Not Recruiting
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
NCT04659603Phase 2Terminated
Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors
NCT01547260Phase 1CompletedPrimary
Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer
NCT02391662Phase 2CompletedPrimary
Nab-paclitaxel and Gemcitabine, in Elderly Patients Untreated Metastatic Pancreatic Adenocarcinoma
NCT03152487Not ApplicableCompletedPrimary
Trial Comparing EUS-guided Radiofrequency Ablation vs. EUS-guided Celiac Plexus Neurolysis
Showing all 5 trials